Overview

Endovenous Lidocaine and Serum Cytokines Concentration

Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
0
Participant gender:
All
Summary
Ineffective treatment of postoperative pain may cause organic damage and chronic pain. Nevertheless, opioids, the leading drugs used for this purpose, present side effects that sometimes restrict their usability. In a multimodal context, new postoperative analgesia techniques have been developed focusing in the reduction of opioid use and their adverse effects, as well as postoperative chronic pain prevention. In this background, continuous intravenous infusion of lidocaine during perioperative period has shown to be promising. This trial aimed to compare postoperative analgesia, opioid consumption, duration of ileus and length of hospital stay and IL-1, IL-6, IL-10, α TNF and γ IFN levels in patients undergoing to laparoscopic cholecystectomies who received intravenous lidocaine in comparison to a control group. Intravenous lidocaine in the perioperative period of laparoscopic cholecystectomies was not able to reduce postoperative pain, opioid consumption, and duration of ileus or length of hospital stay. However, its anti-inflammatory effect was evidenced by the significant changes in the studied cytokines.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Universidade Federal de Santa Maria
Collaborator:
Universidade Federal de Santa Catarina
Treatments:
Lidocaine
Pharmaceutical Solutions
Criteria
Inclusion Criteria:

- age over 18 years and

- physical status according to the American Society of Anesthesiologists (ASA) I and II

Exclusion Criteria:

- patients older than 75 years,

- patients with heart disease,

- patients with history of:

- kidney failure,

- liver failure,

- psychiatric disorder,

- chronic use of opioids or medications that could cause induction of liver enzymes
(anticonvulsants).

- the presentation of adverse effects during the intervention or postoperative
complications, and the conversion to open surgery.